Filing Flows › Adaptive Biotechnologies (ADPT) › Q3 2026
Adaptive Biotechnologies (ADPT) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Adaptive Biotechnologies (ADPT) reported revenue of $83.9M for the third quarter 2026 (Q3 2026), -11% from a year earlier and +17% from the quarter before. Operating margin was -0.5%, net earnings $2.8M (3.3% of revenue).
Adaptive Biotechnologies, Q3 2026: revenue $83.9M (-11% year over year), operating margin -0.5%, net earnings $2.8M, operating cash flow $9.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $83.9M | +17% | -11% |
| Operating profit | −$457K | — | -104% |
| Net earnings | $2.8M | — | -71% |
| Operating cash flow | $9.6M | — | — |
| Free cash flow | $7.7M | — | — |
What changed
Revenue was $83.9M in Q3 2026, down 11% year over year and up 17% from the previous quarter.
Operating costs exceeded revenue by $457K, an operating margin of -0.5%. Total costs grew 1% against a revenue fall of 11%. The fastest-growing cost line was Sales & marketing (+15%). Net earnings were $2.9M, down 70% year over year. The effective tax rate was 0.0%. Non-operating items added $3.3M, 116% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $9.6M, 342% of net income including minority interests. Non-cash charges added back $3.6M of depreciation and amortization and $10.4M of share-based compensation. Working capital and other items used $7.2M. Capital expenditures of $1.9M left free cash flow of $7.7M.
Questions
What was Adaptive Biotechnologies' revenue in the third quarter 2026?
Adaptive Biotechnologies (ADPT) reported revenue of $83.9M for the third quarter 2026 (Q3 2026), -11% from a year earlier and +17% from the quarter before.
Was Adaptive Biotechnologies profitable in the third quarter 2026?
Operating loss was $457K (-0.5% of revenue) and net earnings $2.8M.